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compared with GXR, ATX, and MPH in the treatment of children and adolescents 
with ADHD with no overlap in CrIs. Among non-stimulants, although GXR had a 
higher probability of being more efficacious than ATX, their CrIs overlapped.
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Objectives: The objective of this study was to assess the comparative effective-
ness of clomethiazole against diazepam in the treatment of alcohol withdrawal 
syndrome (AWS) in the real-world. MethOds: Following a retrospective design, 
this study is based on case report notes of patients consecutively treated for AWS 
at a University Clinic in Germany (Aachen), from 2008 to 2013. The primary out-
comes were: scores of German version of the revised clinical institute withdrawal 
assessment for alcohol scale (CIWA-Ar) in the first four days of therapy; duration 
of therapy; duration of hospital stay and rates of complications. Patients in the two 
groups (diazepam and clomethiazole) were matched for demographic factors and 
severity of withdrawal using propensity scores. Results: Seventy nine patients 
(Diazepam = 42; Clomethiazole = 37) were included. Mean age of patients (M = 
69%, F = 30.4%) was 45±15 years. Duration of excessive alcohol use was 16 ± 12 
years. On admission mean systolic and diastolic blood pressure was 139±20 and 
88±13, respectively. Pulse rate was 100 ±18 per minute. CIWA-Ar scores at the end 
of each of the first four days of therapy were not statistically significantly different 
(ANOVA, p < 0.5) for the two therapies. Average duration of therapy was 3.81±2.9 
days vs. 5.8 ±3.2 days (ANOVA - F = 8.6, p = 0.004), for clomethiazole and diazepam 
groups, respectively. Duration of hospital stay was 14.92±10.1 vs. 15±13 (ANOVA – 
F, p > 0.2), respectively. There was no difference in complication rates, except for 
seizures (higher in Diazepam group, Chi-square test, p = 0.023). cOnclusiOns: 
Clomethiazole and Diazepam seem to offer comparable effectiveness in resolving 
symptoms of AWS. Otherwise the notably shorter therapy duration and lower rates 
of complications for clomethiazole hints at some advantages such as faster recovery 
and lower costs of treatment, although this would have to be confirmed in future.
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Objectives: To understand the potential predictors of remission among patients 
treated for major depressive disorder (MDD) in a naturalistic clinical setting in 
the Middle East. MethOds: Data for this post-hoc analysis were taken from a 
6-month prospective, non-interventional, observational study that involved 1,549 
MDD patients without sexual dysfunction at baseline in twelve countries world-
wide (n= 314 in the Middle East). Depression severity was measured using Clinical 
Global Impression of Severity (CGI-S) and 16-item Quick Inventory of Depressive 
Symptomatology Self-Report (QIDS-SR16). Depression-related pain was measured 
using the pain-related-items of Somatic Symptom Inventory (SSI). Remission was 
defined as a QIDS-SR16 score ≤ 5. Generalised estimating equation (GEE) regres-
sion model was used to examine baseline factors associated with remission at 
each follow-up visit. The model included age, sex, region, CGI-S score, QIDS-SR16 
total score, SSI pain total score, and treatment (duloxetine vs. a selective serotonin 
reuptake inhibitor [SSRI] ) at baseline. Other baseline factors were also included if 
they appeared to be significant at p< 0.1 in simple GEE models. The model analysed 
the patient observations up to the point where their initial medications were main-
tained. Results: Of the 240 patients analysed, 133 (55.4%) initiated duloxetine and 
107 (44.6%) initiated an SSRI at baseline. Of these, 199 patients achieved remission 
at any visit during follow-up (91.0% in the duloxetine group and 72.9% in the SSRI 
group, p< 0.001). The GEE results showed that higher QIDS-SR16 scores at baseline 
(odds ratio [OR]= 0.88, p= 0.002) and more MDD episodes in the past 24 months 
(OR= 0.77, p< 0.001) were negatively associated with remission, whereas treatment 
with duloxetine (vs. SSRIs) was positively associated with remission (OR= 2.78, 
p< 0.001). cOnclusiOns: Treatment with duloxetine (vs. SSRIs), a lower level of 
depression severity and fewer previous MDD episodes appeared to be strong predic-
tors of achieving remission in the treatment of MDD in the Middle East.
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Objectives: Obsessive compulsive disorder (OCD) is the fourth most common 
mental disorder in the UK with a prevalence of 1.5%. Both pharmacological and 
psychological interventions are used in the treatment with the treatment course 
usually chronic. This study estimates the relative efficacy of pharmacological 
and psychological treatments or combinations of both. MethOds: A systematic 
review was conducted to identify RCTs of clomipramine, SSRIs, venlafaxine, and 
psychological interventions with a behavioural, cognitive or cognitive behavioural 
component. A Bayesian random effects network meta-analyses (NMA) was used to 
obtain coherent estimates of relative efficacy of every pair of the different inter-
ventions, even when direct evidence was not available. The primary endpoint was 
mean change in Yale-Brown obsessive compulsive scale (YBOCS). We assumed that 
treatment effects for the different SSRIs were similar in the sense that they came 
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Objectives: MyCognition has already demonstrated that its adaptive video game 
programmes are able to enhance cognitive health in healthy volunteers (FENS, July 
2014). It is now using the same technology to assess and train cognitive health 
in psychiatric and neurological patient populations that have cognitive impair-
ment. MethOds: In both the psychiatric and neurological patient population it is 
planned that all with have their cognitive health assessed prior to commencement 
of the study to provide a baseline score. This will be for the 5 key cognitive domains 
(attention, psychomotor speed, episodic memory, working memory and executive 
functioning). All will then be randomised to either active or control group. The 
active group comprises adaptive video training of at least one hour per week over 
a 12-week period on top of standard care. The control group receives standard care 
alone. All the subjects will have their cognitive health assessed at 0, 4, 8 and 12 
weeks. They will also have their condition assessed via a specific scale, e. g., PANS for 
Schizophrenia, UPDRS for Parkinson’s. The results will be calculated as change from 
baseline for both groups at 4, 8 and 12 weeks. Results: In previous tests in healthy 
volunteers a significant improvement in cognitive health was seen after 4 weeks of 
training. By 8 weeks it was possible to see a dose response to the duration of training, 
with longer training showing a greater effect. cOnclusiOns: Detrimental cognitive 
health is seen in many neuropsychiatric conditions. To date, drug therapies have 
had a poor impact on cognitive disorders. This adaptive video training programme 
presents a potential therapeutic intervention that is safe and effective. The online 
assessment can be used to profile at risk subjects and the training could be used to 
prevent as well as treat cognitive decline.
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Objectives: The costs of mental health care for patients with severe and com-
plex personality disorders are high. It is likely that currently, these patients are 
not treated effectively due to limited early recognition. The aim of this study is to 
develop a set of criteria to match patients with severe and complex personality dis-
orders to effective treatment in highly specialized treatment programs. MethOds: 
The subsequent steps consisted of conducting a literature search, applying concept 
mapping, arranging an expert-meeting and validating the set of criteria. After the 
literature search, concept mapping, using cluster analysis and multidimensional 
scaling, was conducted. Goodness of fit and reliability were tested. A consensus 
meeting was arranged to determine cut-off points and operationalize the clus-
ters. In this way, the definite set of criteria for matching patients with severe and 
complex personality disorder was developed. A pilot study on the checklist was 
conducted, including 20 therapists evaluating 45 patients and subsequently a valida-
tion study at 8 mental health institutes was performed. Additionally, a methodology 
to obtain sets of criteria for other psychiatric diagnoses was developed. Results: 
After the literature search and concept mapping, 6 different categories of criteria 
were defined. The concept mapping model provided a good fit (stress value= 0.30) 
and reliability (ρ = 0.49) was reasonably high. The bridging values were on general 
low, indicating homogeneity. The pilot study indicated that clinical judgment and 
the outcome of the checklist correlated high (0.8). The validation study has been 
accomplished at 8 mental health institutes in the Netherlands. The analysis con-
cerning the validation study is now being conducted and the first results will be 
available in August 2014. cOnclusiOns: The method is systematic, structured and 
repeatable and the results of the pilot study are promising. The protocol will provide 
an instrument to develop sets of criteria for other disorders to increase matching of 
patients in mental health care to (cost) effective interventions.
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Objectives: This study compared the clinical efficacy of ADHD treatments in chil-
dren and adolescents. MethOds: A systematic literature review was conducted, 
according to National Institute for Health and Care Excellence guidelines, to identify 
randomized controlled trials (RCTs) of guanfacine (GXR), atomoxetine (ATX), lisdexa-
mfetamine (LDX), and methylphenidate (MPH) extended release (ER) and immediate 
release (IR) in children and adolescents with ADHD. A Bayesian mixed treatment 
comparison was conducted to compare baseline-to-endpoint change in ADHD-
RS-IV score, response (defined as a clinician global impressions – improvement 
[CGI-I] score ≤ 2), with meta-regression adjustments permitted by data availability 
(age and percent female). 95% credible intervals (CrIs) for treatment effects and 
the posterior probability that GXR was more efficacious than each treatment were 
estimated. Results: Of 5,619 records retrieved, 29 RCTs met the inclusion criteria. 
Five trials included GXR, 4 included LDX, 16 included ATX, 7 included MPH-ER, and 
5 included MPH-IR. Per-arm patient sample size ranged from 29 to 222. The mean 
ADHD-RS-IV score change from baseline and 95% CrI (active minus placebo) were 
-8.68 (-10.63, -6.72) for GXR, -14.98 (-17.14, -12.80) for LDX, -6.88 (-8.22, -5.49) for ATX, 
and -9.33 (-11.63, -7.04) for MPH-ER. The relative risk and 95% CrI for CGI-I response 
(drug vs placebo) were 2.13 (1.68, 2.59) for GXR, 2.93 (2.47, 3.40) for LDX, 2.30 (1.79, 
2.81) for MPH-ER, 1.97 (1.43, 2.58) for ATX, and 1.66 (1.02, 2.32) for MPH-IR. Among 
non-stimulants, GXR was more effective than ATX when comparing ADHD-RS-IV 
change (with a posterior probability of 93.91%) and CGI-I response (posterior prob-
ability 71.01%). cOnclusiOns: This review found that LDX had greater efficacy 
